Literature DB >> 24832478

Advances in the treatment of cerebral venous thrombosis.

J M Coutinho1, S Middeldorp, J Stam.   

Abstract

OPINION STATEMENT: Patients with recent cerebral venous sinus thrombosis (CVT) should be fully anticoagulated with heparin as soon as the diagnosis is confirmed, even in the presence of cerebral hemorrhagic venous infarcts. Fixed-dose subcutaneous low-molecular-weight heparins (LMWH) in therapeutic dosage have a better safety profile and are probably more effective than dose-adjusted intravenous unfractionated heparin. After the patient is stabilized , oral anticoagulant treatment is started, aimed at an INR value between 2.0 and 3.0 for at least three months after the acute phase. Since about 40 % of patients with CVT have epileptic seizures at onset or during the first days, many require treatment with anti-epileptics. Prophylactic anti-epileptic treatment is an option, but its efficacy has not been investigated. If no new seizures occur after the acute phase, anti-epileptics can be tapered after three to six months. The efficacy of endovascular treatment, with mechanical and/or pharmacologic thrombolysis, has only been published in small case series, and cannot be regarded as proven effective treatment for CVT. Its theoretical advantage of more rapid clearance of thrombi may be offset by severe bleeding complications, and the limited availability and higher cost of the procedure. Patients who deteriorate because of large space-occupying venous infarcts have a high risk of dying from cerebral herniation. In such cases an emergent decompressive hemicraniectomy is often life-saving. Experience from different centers with this procedure shows a good clinical outcome in the majority of these patients. Patients with CVT may develop - and sometimes present with - chronic intracranial hypertension with headache and papilledema. In such patients the priority is prevention of visual function loss; intracranial hypertension should be controlled with acetazolamide, and occasionally with repeated lumbar punctures if vision is threatened. Refractory cases will need a CSF shunting procedure.

Entities:  

Year:  2014        PMID: 24832478     DOI: 10.1007/s11940-014-0299-0

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  24 in total

Review 1.  Cerebral venous thrombosis: an update.

Authors:  Marie-Germaine Bousser; José M Ferro
Journal:  Lancet Neurol       Date:  2007-02       Impact factor: 44.182

2.  Audit of control of heparin treatment.

Authors:  A G Fennerty; P Thomas; G Backhouse; P Bentley; I A Campbell; P A Routledge
Journal:  Br Med J (Clin Res Ed)       Date:  1985-01-05

3.  Heparin treatment in sinus venous thrombosis.

Authors:  K M Einhäupl; A Villringer; W Meister; S Mehraein; C Garner; M Pellkofer; R L Haberl; H W Pfister; P Schmiedek
Journal:  Lancet       Date:  1991-09-07       Impact factor: 79.321

4.  EFNS guideline on the treatment of cerebral venous and sinus thrombosis in adult patients.

Authors:  K Einhäupl; J Stam; M-G Bousser; S F T M De Bruijn; J M Ferro; I Martinelli; F Masuhr
Journal:  Eur J Neurol       Date:  2010-10       Impact factor: 6.089

5.  Unfractionated or low-molecular weight heparin for the treatment of cerebral venous thrombosis.

Authors:  Jonathan M Coutinho; José M Ferro; Patrícia Canhão; Fernando Barinagarrementeria; Marie-Germaine Bousser; Jan Stam
Journal:  Stroke       Date:  2010-10-07       Impact factor: 7.914

Review 6.  Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism.

Authors:  Petra Mg Erkens; Martin H Prins
Journal:  Cochrane Database Syst Rev       Date:  2010-09-08

Review 7.  Monitoring of unfractionated heparin in critically ill patients.

Authors:  R Aarab; J van Es; A C J M de Pont; M B Vroom; S Middeldorp
Journal:  Neth J Med       Date:  2013-11       Impact factor: 1.422

8.  Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT).

Authors:  José M Ferro; Patrícia Canhão; Jan Stam; Marie-Germaine Bousser; Fernando Barinagarrementeria
Journal:  Stroke       Date:  2004-02-19       Impact factor: 7.914

9.  Cerebral vein and dural sinus thrombosis in adults in Isfahan, Iran: frequency and seasonal variation.

Authors:  M Janghorbani; M Zare; M Saadatnia; S A Mousavi; M Mojarrad; E Asgari
Journal:  Acta Neurol Scand       Date:  2008-02       Impact factor: 3.209

10.  Decompressive hemicraniectomy in severe cerebral venous thrombosis: a prospective case series.

Authors:  Susanna M Zuurbier; Jonathan M Coutinho; Charles B L M Majoie; Bert A Coert; Pepijn van den Munckhof; Jan Stam
Journal:  J Neurol       Date:  2011-11-26       Impact factor: 4.849

View more
  4 in total

1.  Cerebral Venous Sinus Thrombosis : Endovascular Treatment with Rheolysis and Aspiration thrombectomy.

Authors:  P Bhogal; M AlMatter; M Aguilar; I Nakagawa; O Ganslandt; H Bäzner; H Henkes
Journal:  Clin Neuroradiol       Date:  2016-09-12       Impact factor: 3.649

Review 2.  Endovascular treatments for cerebral venous sinus thrombosis.

Authors:  Zhongming Qiu; Hongfei Sang; Qiliang Dai; Gelin Xu
Journal:  J Thromb Thrombolysis       Date:  2015-10       Impact factor: 2.300

3.  Diffuse Subarachnoid Hemorrhage Secondary to Cerebral Venous Sinus Thrombosis.

Authors:  Brian Anderson; Shyamsunder Sabat; Amit Agarwal; Krishnamoorthy Thamburaj
Journal:  Pol J Radiol       Date:  2015-06-01

4.  HELLP Syndrome and Cerebral Venous Sinus Thrombosis Associated with Factor V Leiden Mutation during Pregnancy.

Authors:  Zeynep Ozcan Dag; Yuksel Işik; Yavuz Simsek; Ozlem Banu Tulmac; Demet Demiray
Journal:  Case Rep Obstet Gynecol       Date:  2014-09-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.